Axsome Therapeutics, Inc.

Contributing Author

Recent Articles by Axsome Therapeutics, Inc.

Jul-07	Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 AXSM GlobeNewswire
Jun-20	Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month AXSM GlobeNewswire
Jun-18	Axsome Therapeutics to Present Data Spanning the SYMBRAVO (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS) AXSM GlobeNewswire
Jun-16	Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders AXSM GlobeNewswire
Jun-11	Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 AXSM GlobeNewswire
Jun-10	Axsome Therapeutics Announces Availability of SYMBRAVO (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults AXSM GlobeNewswire
Jun-09	Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia AXSM GlobeNewswire
May-29	Axsome Therapeutics to Participate in Upcoming Investor Conferences AXSM GlobeNewswire
May-28	Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting AXSM GlobeNewswire
May-27	Axsome Therapeutics Settles SUNOSI (solriamfetol) Patent Litigation with Hetero Labs Ltd. AXSM GlobeNewswire
May-13	Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone AXSM GlobeNewswire
May-05	Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update AXSM GlobeNewswire